Eurobio Scientific Presents Research on Breast Cancer Treatment Decisions

Eurobio Scientific participated in the European Society for Medical Oncology (ESMO) 2022 congress, presenting new data relevant to breast cancer treatment strategies. The company highlighted research focused on utilizing genetic signatures to guide chemotherapy choices in specific patient groups.

During the industry satellite symposium, Dr. Anastasia Constantinidou presented data regarding the EndoPredict test. This test is designed to aid in making treatment decisions for premenopausal women diagnosed with ER+/HER2- early-stage breast cancer. The aim is to optimize treatment plans and avoid unnecessary interventions.

The findings presented suggest that EndoPredict can provide valuable information to clinicians, helping them to better identify patients who may benefit from specific therapies and those who might be over-treated. This aligns with the broader trend in oncology towards personalized medicine.

Eurobio Scientific continues to focus on developing diagnostic tools that support oncologists in making informed decisions. The company emphasizes the role of scientific evidence in advancing cancer care and improving patient outcomes.